Financial News · Live Terminal

Page 1263 of 2807

Pacira BioSciences Says Exparel Linked to Lower Opioid Use, Healthcare Costs

Pacira BioSciences (PCRX) said Wednesday that a real-world study evaluating Exparel injectable suspension in total shoulder arthroplasty patients showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events.The study analyzed data from July 2019 to December 2024 from more than 6,400 opioid-naive Medicare Advantage patients undergoing outpatient total shoulder arthroplasty and compared outcomes between those given Exparel and those who received standard-of-care analgesia, the company said.Exparel, or bupivacaine liposome, is approved in the US for postsurgical pain management, the company said.Price: $24.43, Change: $+0.07, Percent Change: +0.27%

$PCRX

Wire49d ago

Market Chatter: Chevron Shareholders Reject Proposal for Appointing Independent Board Chair

Chevron (CVX) shareholders have rejected a proposal put forth at the company's annual general meeting that would have required appointing an independent board chair separate from the chief executive officer, Reuters reported Wednesday, citing preliminary voting results.Shareholders approved the appointment of all 12 nominees to the board and rejected two other shareholder proposals, the report stated.All voting results at the meeting were in line with what the company has recommended, according to the report.Chevron did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $181.36, Change: $-3.35, Percent Change: -1.81%

$CVX

Asia Markets49d ago

Asian Equities Traded in US as ADRs Fall in Wednesday Trading

Asian equities traded in the US as American depositary receipts fell Wednesday with the S&P Asia 50 ADR Index dropping 0.4% to 2,872.69.From North Asia, the gainers were led by fintech firms Qfin Holdings (QFIN) and LexinFintech (LX), which surged 24% and 10%, respectively. They were followed by internet and data center services provider VNET Group (VNET) and social media platform JOYY (JOYY), which advanced 9% and 4.3%, respectively.The decliners from North Asia were led by video display maker LG Display (LPL) and mobile big data platform Aurora Mobile (JG), which shed 11% and 9%, respectively. They were followed by semiconductor companies Himax Technologies (HIMX) and Silicon Motion Technology (SIMO), which dropped 5.1% and 4.6%, respectively.From South Asia, the gainers were led by fintech firm Trident Digital Tech (TDTH) and IT firm Infosys (INFY), which climbed 23% and 2.3%, respectively. They were followed by tech conglomerate Sea (SE) and telecommunications operator Telekomunikasi Indonesia (TLK), which were up 1% and 0.7%, respectively.The decliners from South Asia were led by computer hardware maker Canaan (CAN) and lender HDFC Bank (HDB), which fell 3% and 2.6%, respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories (RDY) and IT company Sify Technologies (SIFY), which were down 1.4% and 1.1%, respectively.

$CAN$HDB$HIMX$INFY$JG$JOYY$LPL$LX$QFIN$RDY$SE$SIFY$SIMO$TDTH$TLK$VNET

Wire49d ago

Palvella Therapeutics Gets US Patent Supporting QTORIN Pitavastatin Through 2043

Palvella Therapeutics (PVLA) said Wednesday the United States Patent and Trademark Office has issued a patent, exclusively licensed from Yale University, supporting Palvella's QTORIN pitavastatin program for porokeratosis, including disseminated superficial actinic porokeratosis.QTORIN pitavastatin is an investigational topical therapy designed to enable pathogenesis-directed inhibition of the mevalonate pathway on-target and directly within affected skin tissue in porokeratosis, according to the company.The patent covers topical administration of HMG-CoA reductase inhibitors, including pitavastatin, for the treatment of porokeratosis, providing protection into 2043 for this pathogenesis-directed treatment approach, the company said.Palvella said it has also filed an additional patent application covering the QTORIN-derived formulation of pitavastatin and other statins and methods of use.Price: $116.72, Change: $-0.88, Percent Change: -0.74%

$PVLA

Wire49d ago

Energy Vault Completes Acquisition of 850 MW Japan Energy Storage Portfolio From BayWa

Energy Vault (NRGV) said Wednesday it completed its acquisition of an 850 megawatt battery energy storage system development portfolio in Japan from BayWa.The deal provides Energy Vault with an in-country platform, a project pipeline, and a local development team, the company said.The portfolio includes about 350 megawatts of advanced-stage battery energy storage system projects expected to reach notice to proceed in the second half of 2027, with commercial operation dates expected to begin in mid-2028.Additionally, 500 megawatts of early-stage projects provide a multi-year development runway, the company said.Price: $5.33, Change: $+0.08, Percent Change: +1.52%

$NRGV

Wire49d ago

Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease

Altimmune (ALT) said Wednesday that data from the phase 2b trial of pemvidutide to treat liver disease demonstrated improvements across non-invasive tests of metabolic dysfunction-associated steatohepatitis activity and fibrosis at 24 weeks compared with placebo.AI-based pathology showed that pemvidutide treatment led to considerable reductions in fibrosis values compared with placebo, according to a statement.The company will start patient enrollment for its phase 3 trial of the drug in H2 based on the latest phase 2b results, according to the company.Price: $2.99, Change: $+0.06, Percent Change: +2.05%

$ALT

Commodities49d ago

Market Chatter: KPI Green Energy Targets $1 Billion Fundraising via Infrastructure Trust

India-based KPI Green Energy intends to raise up to $1 billion by launching a renewable-asset-backed infrastructure investment trust, Reuters reported Tuesday, citing a company executive.The move is expected to help the renewable energy company, based in Gujarat state, broaden its capital base at a time when the country is eyeing 500 gigawatts of clean energy capacity by the end of 2030.The trust is likely to launch around the end of FY27-28, with plans to initially raise between 80 billion Indian rupees ($838.16 million) and 100 billion Indian rupees, according to Faruk Patel, chairman and managing director of the parent company, KP Group.The infrastructure investment trust is expected to hold operational solar, wind, and hybrid power assets of up to 1.5 GW to 2 GW capacity, including projects backed by long-term power supply agreements with state-backed utilities, the report said.KP Group did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

International49d ago

May Dallas Fed Service Sector Index -7.7 vs. Expected -6.0, Prior -9.9 Reading

Wire49d ago

Abacus Global Management, Manning & Napier Form Strategic Alliance

Abacus Global Management (ABX) and Manning & Napier said Wednesday they have entered a strategic alliance agreement and announced the closing of Abacus's minority equity investment of about $53 million in Manning & Napier.The companies said the partnership aims to create value in three core areas, including lead generation and referrals, product development and distribution, and joint client solutions.The agreement allows both companies to collaborate more closely by combining Abacus's longevity data and actuarial expertise with Manning & Napier's investment management and financial planning capabilities, the companies added.Price: $9.58, Change: $+0.02, Percent Change: +0.21%

$ABX

Research49d ago

Research Alert: Abercrombie Posts Mixed Fq1; Maintains Full-year Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ANF posted Q1 2026 EPS of $1.47 vs. $1.59 prior year, $0.18 above consensus despite a Y/Y decline. Net sales reached a record $1.114B (+2% Y/Y), $9M above estimates, marking the 14th consecutive quarter of growth though comparable sales declined 1%. We believe ANF is deserving of a P/E multiple well above 10x, trading at just 7x the midpoint of full-year EPS guidance and below peers despite improving fundamentals. Management maintained full-year guidance of 3-5% revenue growth, 12.0-12.5% operating margin, and EPS of $10.20-$11.00. Regional performance showed divergence with Americas (+3% Y/Y) and APAC (+24% Y/Y) driving growth while EMEA declined 10% due to Middle East conflict impact. Operating margin compressed 130 bps to 8.0% from tariff pressures. The company repurchased $105M in shares during Q1 with $745M remaining on authorization. We expect ANF to continue aggressive share buybacks at current valuation levels.

$ANF

Wire49d ago

Veeva Says Teva Pharmaceutical, Merck KGaA Select its Vault CRM

Veeva Systems (VEEV) said Wednesday that Teva Pharmaceutical (TEVA) and Germany-based Merck KGaA have committed to use its Vault CRM software globally.Vault CRM is an application for life sciences companies that connects sales, marketing, and medical teams on a single platform, Veeva said.Financial terms of the agreements were not disclosed.Shares of Veeva were up by more than 3% in Wednesday trading.Price: $163.01, Change: $+4.47, Percent Change: +2.82%

$TEVA$VEEV

Oil & Energy49d ago

US Oil Update: Crude Dips as Iran State TV Reveals Details of Draft Peace Framework

Crude oil futures dipped on Wednesday following a report by Iran State TV, reported by media outlets, that a draft peace framework it has seen would require Iran to normalize shipping via the Strait of Hormuz within a month of its signing.Front-month West Texas Intermediate crude futures dipped 4.8% to $89.39 per barrel, while Brent futures fell 3.29% to $95.56/bbl.The draft would also require the US would to lift its naval blockade and withdraw nearby military forces, according to the media reports.Macquarie strategists note that a credible, verified deal could trigger a sharp, short-lived sell-off, knocking roughly $20 off oil prices within a week.However, energy trading desks remain deeply skeptical following several false dawns in the conflict.HFI Research emphasized that due to the logistics of a 60-day negotiation window, no meaningful volume of shut-in Middle Eastern crude will set sail before mid-summer, even if a deal is signed immediately.The market now awaits official inventory data from the US Energy Information Administration.The diplomatic rumors follow a sharp military escalation on Tuesday, when US Central Command launched "self-defense" strikes against Iranian missile batteries and mine-laying fast-attack craft.Iran's Islamic Revolutionary Guard Corps retaliated immediately, reportedly engaging a US F-35 fighter jet and downing several American surveillance drones.

Wire49d ago

Abbott Gets CE Mark for Glucose-Ketone Sensing Technology for Diabetes

Abbott (ABT) said Wednesday it has secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes.The systems, branded as Libre Duo and Libre Duo 10 Day, are designed to continuously measure glucose and ketone levels every minute, the company said.Abbott said it plans to start launching Libre Duo systems in some European countries later this year.Price: $86.44, Change: $-0.23, Percent Change: -0.27%

$ABT

Wire49d ago

Roku Introduces New TV Home Screen

Roku (ROKU) said Wednesday it is rolling out a new Home Screen that enables "less time searching and more time streaming."The new Roku Home Screen recommends content based on the viewers' interests using intelligence models, the company said.Roku said the new Home Screen will be initially rolled out across all Roku TVs and streaming devices in the US and is expected to reach over 100 million streaming households soon.Roku shares were up 2.5% in Wednesday trading.Price: $130.78, Change: $+3.17, Percent Change: +2.48%

$ROKU

Wire49d ago

Corcept Therapeutics to Resubmit New Drug Application for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics (CORT) said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.The company said it will resubmit the NDA based on positive outcomes of additional analyses of the application data, which were conducted following issuance of a complete response letter.The FDA notified the company to expect a Prescription Drug User Fee Act date six months following the application submission, according to a statement.Price: $64.86, Change: $+4.50, Percent Change: +7.46%

$CORT

Wire49d ago

Ingredion Says 96% of its Tier 1 Priority Crops Are Now Sustainably Sourced

Ingredion (INGR) said Wednesday that more than 96% of its tier 1 priority crops are now sustainably sourced, up from 25% five years ago.Ingredion also said it has diverted about 95% of total waste from landfills and has achieved zero waste to landfills, defined as less than 0.5% of the plant's solid waste going to landfill or waste incineration without energy recovery, at 16 manufacturing facilities.Shares of the company were up 1.7% in Wednesday trading.Price: $104.44, Change: $+1.14, Percent Change: +1.10%

$INGR

Wire49d ago

Macquarie Adjusts Price Target on Zscaler to $172 From $210, Maintains Outperform Rating

Zscaler (ZS) has an average rating of buy and mean price target of $199.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $127.46, Change: $-57.15, Percent Change: -30.96%

$ZS

Wire49d ago

Tigress Financial Raises Nvidia Price Target to $425 From $360, Maintains Strong Buy Rating

Nvidia (NVDA) has an average rating of Buy and mean price target of $305.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $210.39, Change: $-4.47, Percent Change: -2.08%

$NVDA

Wire49d ago

Climb Enters North American Distribution Partnership With Quantum

Climb Global Solutions' (CLMB) Climb subsidiary said Wednesday that it has entered into a distribution partnership for North America with Quantum (QMCO).The partnership will broaden access to Quantum's full product portfolio, Climb said.Financial terms of the partnership were not provided.Shares of Climb were up 2.3% in Wednesday trading, while Quantum stock was down 1.4%.Price: $21.71, Change: $+0.49, Percent Change: +2.31%

$CLMB$QMCO

Insider Trading49d ago

Nova Insider Sold Shares Worth $781,298, According to a Recent SEC Filing

Eitan Oppenhaim, Director, on May 26, 2026, sold 1,504 shares in Nova (NVMI) for $781,298. Following the Form 4 filing with the SEC, Oppenhaim has control over a total of 6,668 ordinary shares of the company, with 6,668 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1109345/000117891326002938/xslF345X05/ownership.xmlPrice: $517.58, Change: $-9.67, Percent Change: -1.83%

$NVMI

Showing 25241-25260 of 56133